Published in Br J Cancer on March 01, 1994
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer (2000) 1.56
Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer (1998) 1.28
Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol (2011) 1.13
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg (2013) 0.99
Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg (2006) 0.96
Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics (2012) 0.96
Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract Radiat Oncol (2012) 0.94
Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut (1997) 0.94
Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg (2008) 0.91
Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today (2013) 0.89
Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford) (2015) 0.87
Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol (2010) 0.86
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol (2014) 0.86
Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol (2012) 0.84
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. J Transl Med (2014) 0.81
Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol (2012) 0.80
Predictors of the patency of self-expandable metallic stents in malignant gastroduodenal obstruction. World J Gastroenterol (2015) 0.79
53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer (2013) 0.79
Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. PLoS One (2016) 0.78
Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. J Korean Med Sci (2015) 0.77
Adenocarcinoma arising from jejunal ectopic pancreas mimicking peritoneal metastasis from colon cancer: a case report and literature review. Surg Case Rep (2015) 0.75
Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget (2016) 0.75
Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft. BMC Complement Altern Med (2014) 0.75
Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. PLoS One (2016) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med (1965) 12.88
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg (1990) 7.04
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Cancer of the pancreas. 50 years of surgery. Cancer (1987) 3.13
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology (1986) 1.63
Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg (1983) 1.27
Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer (1978) 1.16
CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer (1988) 1.13
Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer (1990) 0.96
Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease. Gut (1980) 0.96
A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas (1988) 0.93
CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers (1989) 0.91
Lewis blood-type may affect the incidence of gastrointestinal cancer. Lancet (1982) 0.89
Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy. Cancer (1978) 0.86
Tumour markers in pancreatic cancer. Ann Chir Gynaecol (1989) 0.83
Relevant factors in the prognosis of ductal pancreatic carcinoma. Acta Chir Scand (1991) 0.81
[CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Dtsch Med Wochenschr (1984) 0.81
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Fibronectin binds to Staphylococcus aureus. Nature (1978) 4.39
Fibroblast surface antigen: a new serum protein. Biochim Biophys Acta (1973) 2.71
Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology (1999) 2.56
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest (1999) 2.32
The release of amino acids with proposed neurotransmitter function from the cuneate and gracile nuclei of the rat in vivo. Brain Res (1974) 2.24
Bacterial plasminogen activators and receptors. FEMS Microbiol Rev (2001) 2.19
Sequential appearance of fibronectin and collagen in experimental granulation tissue. Lab Invest (1980) 2.16
Hydrophobic domains affect the collagen-binding specificity and surface polymerization as well as the virulence potential of the YadA protein of Yersinia enterocolitica. Mol Microbiol (1993) 2.13
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Binding of human fibronectin to group A, C, and G streptococci. Infect Immun (1983) 2.01
Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol (1984) 1.98
Type V collagen as the target for type-3 fimbriae, enterobacterial adherence organelles. Mol Microbiol (1990) 1.94
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
The O75X adhesin of uropathogenic Escherichia coli is a type IV collagen-binding protein. Mol Microbiol (1989) 1.87
Attachment of staphylococci and streptococci on fibronectin, fibronectin fragments, and fibrinogen bound to a solid phase. Infect Immun (1985) 1.86
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
The distribution and axonal transport of free amino acids and related compounds in the dorsal sensory neuron of the rat, as determined by the dansyl reaction. J Neurochem (1973) 1.70
Adhesion protein YadA of Yersinia species mediates binding of bacteria to fibronectin. Infect Immun (1992) 1.66
Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer (1984) 1.56
Functional mapping of the Yersinia enterocolitica adhesin YadA. Identification Of eight NSVAIG - S motifs in the amino-terminal half of the protein involved in collagen binding. Mol Microbiol (2000) 1.55
Purification and characterisation of a plasmin-sensitive surface protein of Staphylococcus aureus. Eur J Biochem (1996) 1.54
Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol (2000) 1.51
Effective dose during screening monitored intussusception reduction. Clin Radiol (1993) 1.47
Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer (1986) 1.45
Immunological interspecies cross-reactions of fibroblast surface antigen (fibronectin). Immunochemistry (1976) 1.44
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer (1986) 1.44
Binding sites for streptococci and staphylococci in fibronectin. Infect Immun (1984) 1.41
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res (2002) 1.36
Isolation of a tryptic fragment containing the collagen-binding site of plasma fibronectin. J Biol Chem (1979) 1.35
Affinity requirements for antibody assays mapped by monoclonal antibodies. J Immunol (1983) 1.33
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 1.32
The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology (1999) 1.32
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. Eur J Pharmacol (1993) 1.30
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer (1987) 1.30
Demonstration of fibronectin in human cerebrospinal fluid. J Lab Clin Med (1978) 1.28
Polypeptides of a glycoprotein antigen (SF) present in serum and surface of normal but not of transformed chicken fibroblasts. Biochim Biophys Acta (1975) 1.25
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer (1991) 1.25
Fibroblast surface antigen (SF): molecular properties, distribution in vitro and in vivo, and altered expression in transformed cells. J Supramol Struct (1976) 1.23
Presynaptic gamma-aminobutyric acid receptors in the rat anococcygeus muscle and their antagonism by 5-aminovaleric acid. Br J Pharmacol (1982) 1.22
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol (2001) 1.22
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Development of brown fat cells in monolayer culture. I. Morphological and biochemical distinction from white fat cells in culture. Exp Cell Res (1983) 1.19
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer (1989) 1.18
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Purification and analysis of mitochondrial membrane proteins on nondenaturing gradient polyacrylamide gels. Anal Biochem (1986) 1.14
Reliability of radiographs in defining union of internally fixed fractures. Injury (2004) 1.13
Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infect Immun (1995) 1.12
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res (1992) 1.11
Expression of pls, a gene closely associated with the mecA gene of methicillin-resistant Staphylococcus aureus, prevents bacterial adhesion in vitro. Infect Immun (2001) 1.11
Interaction of Haemophilus influenzae with the mammalian extracellular matrix. J Infect Dis (1996) 1.11
Binding of plasminogen to Neisseria meningitidis and Neisseria gonorrhoeae and formation of surface-associated plasmin. J Infect Dis (1992) 1.10
A novel lectin-independent interaction of P fimbriae of Escherichia coli with immobilized fibronectin. FEBS Lett (1989) 1.10
Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience (1993) 1.10
Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest (1988) 1.10
Prostaglandin and noradrenaline interactions in rat brain synaptosomes [proceedings]. Br J Pharmacol (1979) 1.09
Demonstration and biochemical characterisation of rat brain NADPH-dependent diaphorase. J Neurochem (1988) 1.09
Does the type of flooring affect the risk of hip fracture? Age Ageing (2004) 1.09
Development of cytochrome b and an active oxidase system in association with maturation of a human promyelocytic (HL-60) cell line. J Cell Biol (1982) 1.08
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. J Immunol (1989) 1.06
The relationship between the keratocyst antigen (KCA) and keratin. J Oral Pathol (1986) 1.06
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
The uptake and release of [3-H]-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthlane (ADTN) by striatal nerve terminals. Br J Pharmacol (1978) 1.06
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer (1986) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer (1994) 1.03
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Multifunctional nature of P fimbriae of uropathogenic Escherichia coli: mutations in fsoE and fsoF influence fimbrial binding to renal tubuli and immobilized fibronectin. Mol Microbiol (1991) 1.03
Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am J Physiol (1998) 1.02
Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol (1992) 1.02
Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res (1996) 1.01
Childhood cancer and paternal exposure to ionizing radiation: preliminary findings from the Oxford Survey of Childhood Cancers. Am J Ind Med (1993) 1.01
Rat brain NADPH-dependent diaphorase. A possible relationship to cytochrome P450 reductase. Biochem Pharmacol (1988) 1.00
Agonist-induced internalization of the metabotropic glutamate receptor 1a is arrestin- and dynamin-dependent. J Neurochem (2001) 0.99
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
High affinity l-[3h]glutamate binding to postsynaptic receptor sites on rat cerebellar membranes. J Neurochem (1978) 0.99
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer (1987) 0.98
Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol (1992) 0.98
Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J Immunol (1988) 0.98
Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum. J Neurochem (1985) 0.98
Demonstration and partial characterization of a novel soluble antigen present in keratocysts. Oncodev Biol Med (1982) 0.98
Evoked release of amino acids from the intact spinal cord. Br J Pharmacol (1972) 0.97